Kate Rumrill

Kate Rumrill is a seasoned executive, with 30+ years of extensive experience in the Medical Device and Pharmaceutical Industry. She began her career as a Toxicologist with companies such as Sterling Winthrop and Eli Lilly & Company. She later transitioned to focus on clinical research, holding various roles over the years, from CRA to VP. Most recently, Kate was the President and CEO of NeoSync, Inc., a clinical stage company, developing novel non-invasive neuromodulation devices in the CNS space. Prior to that, she held the position of Vice President, Global Medical Affairs with Covidien’s Peripheral Vascular Division. She currently serves as President and CEO of Ablative Solutions, a clinical stage company developing a novel Renal Denervation product for Hypertension.  She has extensive experience in product development and new product launches, most notably through her time at Covidien and Eli Lilly & Company. Kate holds a BS degree in both Biology and Psychology from the State University of New York.